FTO and neoplasm: Xiao et al. demonstrated that an antigen-capturing nanoplatform, which concurrently delivers tumor-associated antigens and the FTO inhibitor (FB23-2) into tumor-infiltrating dendritic cells, significantly enhances tumor-specific immune responses both in vivo and in vitro [108].